

Press release 2013-10-11

## **Foxy-5 study is open but screening procedures delayed for further two weeks**

**WntResearch AB (WNT.ST) announces that the ongoing Foxy-5 study has been delayed in dosing of the first patient due to challenges with technical transfer of immunohistochemistry work on patient's tumor tissue for the pre-screening process. We are collaborating diligently with the Pathology Department at Herlev Hospital and are very close to a solution. We believe we are up and running within 2 weeks -and the Oncology Department is ready as announced earlier to include and treat patients in the trial as soon as the pre-screening has been carried out.**

The company is running the trial at the Oncology Unit at Herlev University Hospital in Denmark in patients with metastatic breast, colorectal or prostate cancers with no or low expression level of the protein called Wnt-5a in their primary tumors. By offering treatment with Foxy-5 to patients with no or low endogenous levels of Wnt-5a the objective is to inhibit the metastatic process. All approvals from authorities are in place and the oncologists and patients are ready as soon as the screening procedures are in place.

### **CEO Nils Brünner comments:**

"We are eager to include the first patient in the ongoing Foxy-5 study and are working diligently with the pathologists to get the technicalities for the screening procedure up and running within the next two weeks. We have designed Foxy-5 to prevent metastases – a feared and often lethal condition for cancer patients."

### **For further information please contact:**

Nils Brünner, CEO  
E-mail: [nbr@wntresearch.com](mailto:nbr@wntresearch.com)  
Telephone: +45 2614 4708

### **About Foxy-5**

Foxy-5 is an anti-metastatic drug in Phase 1. Foxy-5 has a significant market potential within oncology. Foxy-5 represents a first-in-class concept for the treatment of cancer. The study drug targets the metastatic process, which is the primary reason for cancer deaths. Foxy-5 is one of the first antimetastatic products ever to enter clinical trials. Foxy-5 offers a potential paradigm shift to influence the treatment of many large cancer indications including breast-, colon and prostate cancer.

### **About WntResearch AB**

WntResearch (WNT.ST) is a public company listed at AktieTorget. WntResearch is developing novel anti-metastatic therapies for the treatment of cancer patients.